LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company’s Board of Directors approved equity awards to Penny Fleck in connection with

Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia Entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests

LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of 11,111,111 of its ordinary shares at an offering price of $9.00 per share.

Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) MeiraGTx intends to immediately pursue global regulatory filings for approval of bota-vec

Clinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohorts Increases in Unstimulated Whole Saliva Flow Rate (UWSFR) maintained out to 3 years AAV-hAQP1 was

- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for both PRO and objective measures. LONDON and NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx

FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract MeiraGTx to hold a program update and present long-term data for AAV2-hAQP1 program for the treatment of Grade 2/3